Damon Tanton, MD
Endocrinology, Diabetes & Metabolism · Orlando, FLNPI 1952429615
Payments from drug & device makers
Across 1,418 payments — averaging $818.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$444K
- Lilly USA, LLC$341K
- Boehringer Ingelheim$161K
- Amgen$64K
- Medtronic$46K
- Johnson & Johnson$34K
- plus $71K from 17 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 410 | $443,991 |
| Lilly USA, LLC | 520 | $341,161 |
| Boehringer Ingelheim | 173 | $160,738 |
| Amgen(2 entities) | 91 | $64,343 |
| Medtronic(2 entities) | 16 | $45,749 |
| Johnson & Johnson(2 entities) | 47 | $33,993 |
| Bayer | 31 | $26,406 |
| Merck | 19 | $13,397 |
| Insulet Corporation | 48 | $12,670 |
| Xeris Pharmaceuticals, Inc. | 7 | $7,239 |
| Eli Lilly | 2 | $4,713 |
| Sanofi-aventis U.S. LLC | 3 | $2,365 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $1,457 |
| Abbott | 12 | $798 |
| Tandem Diabetes Care, Inc. | 9 | $663 |
| Companion Medical, Inc. | 6 | $400 |
| Cequr Corporation | 3 | $201 |
| Dexcom, Inc. | 5 | $200 |
| Bigfoot Biomedical Inc | 4 | $146 |
| Corcept Therapeutics | 1 | $125 |
| Sanofi Pasteur Inc. | 1 | $92 |
| Senseonics, Incorporated | 1 | $70 |
| Clarus Therapeutics Inc. | 1 | $6 |
How this compares
$1,160,920 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Orlando
- Richard PratleyOrlando$9.2M
- Steven SmithOrlando$7.9M
- Tina ThethiOrlando$3.8M
- Hanford YauOrlando$489K
- Jose MandryOcoee$9.1M
- Barry HorowitzWest Palm Beach$7.1M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.